491 related articles for article (PubMed ID: 23926200)
1. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
4. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
9. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
Boot A; Jiang N; Rozen SG
Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
[TBL] [Abstract][Full Text] [Related]
10. Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid.
Castells X; Karanović S; Ardin M; Tomić K; Xylinas E; Durand G; Villar S; Forey N; Le Calvez-Kelm F; Voegele C; Karlović K; Mišić M; Dittrich D; Dolgalev I; McKay J; Shariat SF; Sidorenko VS; Fernandes A; Heguy A; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1873-81. PubMed ID: 26383547
[TBL] [Abstract][Full Text] [Related]
11. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
12. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
14. Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.
Xiao J; Zhu X; Hao GY; Zhu YC; Hou HJ; Zhang J; Ma LL; Tian Y; Zhang YH
Transplant Proc; 2011 Dec; 43(10):3751-4. PubMed ID: 22172840
[TBL] [Abstract][Full Text] [Related]
15. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
[TBL] [Abstract][Full Text] [Related]
16. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
[TBL] [Abstract][Full Text] [Related]
17. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
Nault JC; Letouzé E
Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.
Yang HY; Yang CC; Wu CY; Wang LJ; Lu KL
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261684
[TBL] [Abstract][Full Text] [Related]
19. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
[TBL] [Abstract][Full Text] [Related]
20. Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.
Aydin S; Dekairelle AF; Ambroise J; Durant JF; Heusterspreute M; Guiot Y; Cosyns JP; Gala JL
PLoS One; 2014; 9(9):e106301. PubMed ID: 25184754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
